Effects of pyran copolymer on oncogenic virus infections in immunosuppressed hosts.
D000818:Animals; D000961:Antilymphocyte Serum; D003588:Cytopathogenic Effect, Viral; D005260:Female; D006084:Graft Rejection; D006385:Hemagglutination Inhibition Tests; D007165:Immunosuppression Therapy; D007372:Interferons / Q000032:analysis / Q000096:biosynthesis; D007942:Leukemia, Experimental / Q000276:immunology*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology*; D011108:Polymers; D011120:Polyomavirus / Q000187:drug effects*; D011247:Pregnancy; D011714:Pyrans / Q000494:pharmacology*; D011817:Rabbits / Q000276:immunology; D011925:Rauscher Virus / Q000187:drug effects*; D016038:Skin Transplantation; D013163:Splenomegaly / Q000517:prevention & control; D013934:Thymectomy; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D014616:Vaccinia virus
D000961:Antilymphocyte Serum; D011108:Polymers; D011714:Pyrans; D007372:Interferons